October 14, 2008

Johnson & Johnson Reports 2008 Third-Quarter Results

NEW BRUNSWICK, N.J., Oct 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sales of $15.9 Billion Increased 6.4% Versus a Year Ago; EPS was $1.17 Excluding 2007 Special Items, 2008 Third-Quarter EPS Increased 10.4%* Johnson & Johnson today announced sales of $15.9 billion for the third quarter of 2008, an increase of 6.4% as compared to the third quarter of 2007. Operational growth was 3.3% and the positive impact of currency was 3.1%. Domestic sales were up .4%, while international sales increased 13.1%, reflecting operational growth of 6.5% and a positive currency impact of 6.6%.

Net earnings and diluted earnings per share for the third quarter of 2008 were $3.3 billion and $1.17, respectively. The third quarter of 2007 included an after-tax restructuring charge of $528 million associated with a cost improvement program. Excluding this charge, net earnings for the current quarter and diluted earnings per share represent increases of 7.6% and 10.4 %, respectively, as compared to the same period in 2007. * The Company increased its earnings guidance for full-year 2008 to $4.50 - $4.53 per share, which does not include the impact of any in-process research and development charges or other special items.

"Johnson & Johnson continues to achieve solid earnings results despite the impact that generic products have had on our Pharmaceutical business," said William C. Weldon, Chairman and Chief Executive Officer. "Of note was the strong sales performance of our Consumer segment and the solid sales results in our Medical Devices and Diagnostics segment."

Worldwide Consumer sales of $4.1 billion for the third quarter represented a 13.1% increase over the prior year with operational growth of 9.4% and a positive impact from currency of 3.7%. Domestic sales increased 11.2%, while international sales increased 14.7%; 8.1% from operations and 6.6% from currency.

Sales results reflect the strong performance of the U.S. launch of ZYRTEC, an over-the-counter allergy treatment; LISTERINE antiseptic mouthrinse; international sales of Baby Care products; and the skin care lines of NEUTROGENA, CLEAN & CLEAR and AVEENO. Also contributing to growth were sales of DABAO, the leading moisturizer in China, which was acquired as part of the recently completed acquisition of Beijing Dabao Cosmetics Co., Ltd., a personal care products company.

Worldwide Medical Devices and Diagnostics sales of $5.7 billion for the third quarter represented an 8.8% increase over the prior year with operational growth of 5.6% and a positive impact from currency of 3.2%. Domestic sales increased 3.1%, while international sales increased 14.3%; 8.0% from operations and 6.3% from currency.

Primary contributors to the operational growth included Diabetes Care's blood glucose monitoring and insulin delivery products; Ethicon Endo-Surgery's minimally invasive products; Vistakon's disposable contact lenses; Ortho-Clinical Diagnostics' professional products; and DePuy's orthopaedic joint reconstruction, sports medicine and trauma businesses. This growth was partially offset by lower sales in the Cordis franchise, reflecting new competitive entries in the drug-eluting stent market.

During the quarter, the Company announced that it had entered into a definitive agreement to acquire SurgRx, a privately held developer of the advanced bipolar tissue sealing system used in the EnSeal family of devices.

Worldwide Pharmaceutical sales of $6.1 billion for the third quarter represented an increase over the prior year of .2% with an operational decline of 2.5% and a positive impact from currency of 2.7%. Domestic sales decreased 6.0%, while international sales increased 10.3%; 3.3% from operations and 7.0% from currency.

Sales growth reflects the strong performance of VELCADE, a treatment for multiple myeloma; REMICADE, a biologic approved for the treatment of a number of immune mediated inflammatory diseases; TOPAMAX, an antiepileptic and a treatment for the prevention of migraine headaches; and RISPERDAL CONSTA, an antipsychotic medication. Sales results of RISPERDAL were negatively impacted by generic competition.

During the quarter, the European Commission granted marketing authorization for INTELENCE, a next generation non-nucleoside reverse transcriptase inhibitor; DORIBAX, an antibiotic used as a treatment for complicated urinary tract infections, complicated intra-abdominal infections, and nosocomial pneumonia including ventilator-associated pneumonia; and for VELCADE, in combination with melphalan and prednisone, for the treatment of patients with previously untreated multiple myeloma. In addition, the Company submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for rivaroxaban, an investigational, oral, once daily anticoagulant for the prevention of deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery. The Company also submitted a supplemental new drug application to the FDA for the combination of DOXIL and Taxotere® for the treatment of women with advanced breast cancer who have received prior anthracycline treatment. In July, the FDA granted pediatric exclusivity for TOPAMAX extending the marketing exclusivity through March 2009.

About Johnson & Johnson

Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our 119,400 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings and diluted earnings per share excluding special items, such as after-tax in-process research and development charges and restructuring charges, are non-GAAP financial measures and should not be considered replacements for GAAP results. For a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures, see the accompanying tables to this release.

NOTE TO INVESTORS

Johnson & Johnson will conduct a meeting with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. The schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises. Additional information on Johnson & Johnson can be found on the Company's website at www.jnj.com.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

    Johnson & Johnson and Subsidiaries
    ----------------------------------
    Supplementary Sales Data

    (Unaudited; Dollars in Millions)                  THIRD QUARTER
    --------------------------------                  -------------
                                                           Percent Change
                                     ----   ----           --------------
                                     2008   2007 Total  Operations  Currency
    ---------------------            ----   ---- -----  ----------  --------
    Sales to customers by
    segment of business

    Consumer
        U.S.                       $1,769  1,591  11.2%       11.2         -
        International               2,330  2,032  14.7         8.1       6.6
    -----------------               -----  -----  ----         ---       ---
                                    4,099  3,623  13.1         9.4       3.7
                                    -----  -----  ----         ---       ---

    Pharmaceutical
        U.S.                        3,538  3,765  (6.0)       (6.0)        -
        International               2,575  2,334  10.3         3.3       7.0
    -----------------               -----  -----  ----         ---       ---
                                    6,113  6,099   0.2        (2.5)      2.7
                                    -----  -----   ---        ----       ---

    Med Devices & Diagnostics
        U.S.                        2,648  2,569   3.1         3.1         -
        International               3,061  2,679  14.3         8.0       6.3
    -----------------               -----  -----  ----         ---       ---
                                    5,709  5,248   8.8         5.6       3.2
                                    -----  -----   ---         ---       ---

    U.S.                            7,955  7,925   0.4         0.4         -
    International                   7,966  7,045  13.1         6.5       6.6
    -------------                   -----  -----  ----         ---       ---
    Worldwide                     $15,921 14,970   6.4%        3.3       3.1
    ---------                     ------- ------   ---         ---       ---



    (Unaudited; Dollars in Millions)                   NINE MONTHS
    --------------------------------                   -----------
                                                            Percent Change
                                     ----   ----            --------------
                                     2008   2007 Total  Operations  Currency
    ---------------------            ----   ---- -----  ----------  --------
    Sales to customers by
    segment of business

    Consumer
        U.S.                       $5,282  4,782  10.5%       10.5         -
        International               6,917  5,901  17.2         7.3       9.9
    -----------------               -----  -----  ----         ---       ---
                                   12,199 10,683  14.2         8.7       5.5
                                   ------ ------  ----         ---       ---

    Pharmaceutical
        U.S.                       11,401 11,659  (2.2)       (2.2)        -
        International               7,481  6,810   9.9           -       9.9
    -----------------               -----  -----   ---           -       ---
                                   18,882 18,469   2.2        (1.5)      3.7
                                   ------ ------   ---        ----       ---

    Med Devices & Diagnostics
        U.S.                        7,959  7,772   2.4         2.4         -
        International               9,525  8,214  16.0         6.0      10.0
    -----------------               -----  -----  ----         ---      ----
                                   17,484 15,986   9.4         4.3       5.1
                                   ------ ------   ---         ---       ---

    U.S.                           24,642 24,213   1.8         1.8         -
    International                  23,923 20,925  14.3         4.3      10.0
    -------------                  ------ ------  ----         ---      ----
    Worldwide                     $48,565 45,138   7.6%        3.0       4.6
    ---------                     ------- ------   ---         ---       ---



    Johnson & Johnson and Subsidiaries
    ----------------------------------
    Supplementary Sales Data


    (Unaudited; Dollars in Millions)              THIRD QUARTER
    --------------------------------              -------------
                                                            Percent Change
                                     ----   ----            --------------
                                     2008   2007 Total  Operations Currency
                                     ----   ---- -----  ---------- --------
    Sales to customers by
    geographic area
    U.S.                           $7,955  7,925   0.4%        0.4        -
    ----                           ------  -----   ---         ---        -

    Europe                          4,076  3,765   8.3         1.0      7.3
    Western Hemisphere excluding
     U.S.                           1,461  1,195  22.3        15.3      7.0
    Asia-Pacific, Africa            2,429  2,085  16.5        11.3      5.2
    --------------------            -----  -----  ----        ----      ---
    International                   7,966  7,045  13.1         6.5      6.6
    -------------                   -----  -----  ----         ---      ---

    Worldwide                     $15,921 14,970   6.4%        3.3      3.1
    ---------                     ------- ------   ---         ---      ---



    (Unaudited; Dollars in Millions)                  NINE MONTHS
    --------------------------------                  -----------
                                                           Percent Change
                                     ----   ----           --------------
                                     2008   2007 Total  Operations Currency
                                     ----   ---- -----  ---------- --------
    Sales to customers by
    geographic area
    U.S.                          $24,642 24,213   1.8%        1.8        -
    ----                          ------- ------   ---         ---        -

    Europe                         12,931 11,485  12.6         1.4     11.2
    Western Hemisphere excluding
     U.S.                           3,986  3,372  18.2         8.4      9.8
    Asia-Pacific, Africa            7,006  6,068  15.5         7.8      7.7
    --------------------            -----  -----  ----         ---      ---
    International                  23,923 20,925  14.3         4.3     10.0
    -------------                  ------ ------  ----         ---     ----

    Worldwide                     $48,565 45,138   7.6%        3.0      4.6
    ---------                     ------- ------   ---         ---      ---



    Johnson & Johnson and Subsidiaries
    Condensed Consolidated Statement of Earnings

    ------------------------------------------------
    (Unaudited; in Millions Except Per
     Share Figures)                         THIRD QUARTER
    ----------------------------------      -------------

                               2008                 2007
                               ----                 ----            Percent
                                  Percent                Percent    Increase
                         Amount  to Sales   Amount      to Sales  (Decrease)
    ------------------   ------  --------   ------      --------   ---------
    Sales to customers  $15,921     100.0  $14,970         100.0         6.4
    ------------------  -------     -----  -------         -----         ---
    Cost of products
     sold                 4,774      30.0    4,274          28.5        11.7
    Selling, marketing
     and administrative
     expenses             5,195      32.6    4,899          32.7         6.0
    Research expense      1,861      11.7    1,834          12.3         1.5
    Restructuring             -         -      745           5.0
    Interest
     (income)
     expense, net            25       0.2      (52)         (0.3)
    Other (income)
     expense, net          (224)     (1.4)       2             -
    --------------         ----      ----        -             -        ----
    Earnings before
     provision for
     taxes on income      4,290      26.9    3,268          21.8        31.3
    Provision for taxes
     on income              980       6.1      720           4.8        36.1
    -------------------     ---       ---      ---           ---        ----
    Net earnings         $3,310      20.8   $2,548          17.0        29.9
    ------------         ------      ----   ------          ----        ----

    Net earnings per
     share  (Diluted)     $1.17              $0.88                      33.0

    Average shares
     outstanding
     (Diluted)          2,831.3            2,912.9

    Effective tax rate     22.8%              22.0%

    ------------------
    Adjusted earnings
     before provision
     for taxes and net
     earnings
      Earnings before
       provision for
       taxes on income   $4,290      26.9   $4,013 (1)      26.8         6.9
      Net earnings       $3,310      20.8   $3,076 (1)      20.5         7.6
      Net earnings per
       share  (Diluted)   $1.17              $1.06 (1)                  10.4
      Effective tax
       rate                22.8%              23.3%
    ---------------        ----               ----

    (1) The difference between as reported earnings and as adjusted earnings
    before provision for taxes on income, net earnings and net earnings per
    share (diluted) is the exclusion of the restructuring expense of $745
    million, $528 million and $0.18 per share, respectively.



    Johnson & Johnson and Subsidiaries
    Condensed Consolidated Statement of Earnings

    ------------------------------------------------
    (Unaudited; in Millions Except Per
     Share Figures)                         NINE MONTHS
    ----------------------------------      -----------

                               2008                   2007
                               ----                   ----           Percent
                                   Percent                Percent    Increase
                        Amount     to Sales   Amount     to Sales  (Decrease)
    ------------------  ------     --------   ------     --------  ----------
    Sales to customers $48,565        100.0  $45,138        100.0        7.6
    ------------------ -------        -----  -------        -----        ---
    Cost of products
     sold               14,139         29.1   13,017         28.8        8.6
    Selling, marketing
     and administrative
     expenses           15,825         32.6   14,730         32.6        7.4
    Research expense     5,469         11.3    5,352         11.9        2.2
    In-process
     research &
     development            40          0.1      807          1.8
    Restructuring            -            -      745          1.7
    Interest
     (income)
     expense, net           57          0.1     (121)        (0.3)
    Other (income)
     expense, net         (377)        (0.8)    (343)        (0.8)
    --------------        ----         ----     ----         ----       ----
    Earnings before
     provision for taxes
     on income          13,412         27.6   10,951         24.3       22.5
    Provision for taxes
     on income           3,177          6.5    2,749          6.1       15.6
    -------------------  -----          ---    -----          ---       ----
    Net earnings       $10,235         21.1   $8,202         18.2       24.8
    ------------       -------         ----   ------         ----       ----

    Net earnings per
     share  (Diluted)    $3.60                 $2.81                     28.1

    Average shares
     outstanding
     (Diluted)         2,847.8               2,919.3

    Effective tax rate    23.7%                 25.1%

    ------------------
    Adjusted earnings
     before provision
     for taxes and net
     earnings
      Earnings before
       provision for
       taxes on income $13,452 (1)     27.7  $12,503 (2)     27.7        7.6
         Net earnings  $10,275 (1)     21.2   $9,537 (2)     21.1        7.7
      Net earnings
       per share
       (Diluted)         $3.61 (1)             $3.27 (2)                10.4
      Effective tax
       rate               23.6%                 23.7%
    ---------------                             ----                    ----

    (1) The difference between as reported earnings and as adjusted earnings
    before provision for taxes on income and net earnings and net earnings
    per share (diluted) is IPR&D of $40 million with no tax benefit and
    $0.01 per share, respectively.

    (2) The difference between as reported earnings and as adjusted earnings
    before provision for taxes on income, net earnings and net earnings per
    share (diluted) is the exclusion of IPR&D of $807 million with no tax
    benefit and $0.28 per share, respectively, and the exclusion of the
    restructuring expense of $745 million, $528 million and $0.18 per share,
    respectively.



                                        REPORTED SALES vs. PRIOR PERIOD
                                        -------------------------------
                                                   $MM
                                                   ---

                                          THIRD QUARTER

                                                    % Change

                  2008   2007   Reported        Operational (1)    Currency
                  ----   ----   --------        ---------------    --------

      PHARMACEUTICAL SEGMENT  (2) (3)
      -------------------------------

      ACIPHEX/PARIET
      --------------
      US           130    159    -18.2%              -18.2%           -
      Intl         152    179    -15.1%              -19.6%         4.5%
      WW           282    338    -16.6%              -19.0%         2.4%

      CONCERTA
      --------
      US           190    177      7.3%                7.3%           -
      Intl         208     54    285.2%              260.0%        25.2%
      WW           398    231     72.3%               66.4%         5.9%

      DURAGESIC/FENTANYL TRANSDERMAL
      ------------------------------
      US            54    107    -49.5%              -49.5%           -
      Intl         205    202      1.5%               -5.4%         6.9%
      WW           259    309    -16.2%              -20.7%         4.5%

      LEVAQUIN/FLOXIN
      ---------------
      US           313    352    -11.1%              -11.1%           -
      Intl          20     19      5.3%                1.4%         3.9%
      WW           333    371    -10.2%              -10.4%         0.2%

      PROCRIT/EPREX
      --------------
      US           334    380    -12.1%              -12.1%           -
      Intl         285    302     -5.6%              -11.8%         6.2%
      WW           619    682     -9.2%              -11.9%         2.7%

      RAZADYNE/REMINYL
      ----------------
      US            31     43    -27.9%              -27.9%           -
      Intl         107     87     23.0%               14.9%         8.1%
      WW           138    130      6.2%                0.7%         5.5%

      REMICADE
      --------
      US           778    648     20.1%               20.1%           -
      US Exports
       (4)         198    171     15.8%               15.8%           -
      Intl           2      -    100.0%              100.0%           -
      WW           978    819     19.4%               19.4%           -

      RISPERDAL/RISPERIDONE
      ----------------------
      US           122    530    -77.0%              -77.0%           -
      Intl         198    301    -34.2%              -38.4%         4.2%
      WW           320    831    -61.5%              -63.0%         1.5%

      RISPERDAL CONSTA
      ----------------
      US           118    111      6.3%                6.3%           -
      Intl         220    183     20.2%               11.9%         8.3%
      WW           338    294     15.0%                9.8%         5.2%

      TOPAMAX
      -------
      US           606    498     21.7%               21.7%           -
      Intl         122    115      6.1%               -0.3%         6.4%
      WW           728    613     18.8%               17.6%         1.2%

      VELCADE
      -------
      US             1      2    -50.0%              -50.0%         0.0%
      Intl         189    128     47.7%               38.3%         9.4%
      WW           190    130     46.2%               36.9%         9.3%

      OTHER
      -----
      US           663    587     12.9%               12.9%           -
      Intl         867    764     13.5%                4.8%         8.7%
      WW         1,530  1,351     13.2%                8.3%         4.9%

      TOTAL PHARMACEUTICAL
      --------------------
      US         3,538  3,765     -6.0%               -6.0%           -
      Intl       2,575  2,334     10.3%                3.3%         7.0%
      WW         6,113  6,099      0.2%               -2.5%         2.7%




                                        NINE MONTHS

                                                % Change


                  2008   2007 Reported       Operational (1)    Currency
                  ----   ---- --------       ---------------    --------

      PHARMACEUTICAL SEGMENT  (2) (3)
      -------------------------------

      ACIPHEX/PARIET
      --------------
      US           399    479    -16.7%           -16.7%           -
      Intl         485    531     -8.7%           -17.0%         8.3%
      WW           884  1,010    -12.5%           -16.9%         4.4%

      CONCERTA
      --------
      US           622    576      8.0%            8.0%            -
      Intl         345    163    111.7%           95.3%         16.4%
      WW           967    739     30.9%           27.3%          3.6%

      DURAGESIC/FENTANYL TRANSDERMAL
      ------------------------------
      US           199    319    -37.6%          -37.6%            -
      Intl         565    581     -2.8%          -11.9%          9.1%
      WW           764    900    -15.1%          -21.0%          5.9%

      LEVAQUIN/FLOXIN
      ---------------
      US         1,117  1,155     -3.3%           -3.3%            -
      Intl          63     59      6.8%            1.8%          5.0%
      WW         1,180  1,214     -2.8%           -3.0%          0.2%

      PROCRIT/EPREX
      --------------
      US         1,014  1,359    -25.4%          -25.4%            -
      Intl         886    898     -1.3%          -11.3%         10.0%
      WW         1,900  2,257    -15.8%          -19.8%          4.0%

      RAZADYNE/REMINYL
      ----------------
      US           123    145    -15.2%          -15.2%            -
      Intl         316    245     29.0%           16.1%         12.9%
      WW           439    390     12.6%            4.5%          8.1%

      REMICADE
      --------
      US         2,138  1,873     14.1%           14.1%            -
      US Exports
       (4)         718    546     31.5%           31.5%            -
      Intl           6      -    100.0%          100.0%            -
      WW         2,862  2,419     18.3%           18.3%            -

      RISPERDAL/RISPERIDONE
      ----------------------
      US         1,196  1,629    -26.6%          -26.6%            -
      Intl         645    917    -29.7%          -36.2%          6.5%
      WW         1,841  2,546    -27.7%          -30.0%          2.3%

      RISPERDAL CONSTA
      ----------------
      US           339    314      8.0%            8.0%            -
      Intl         651    519     25.4%           13.2%         12.2%
      WW           990    833     18.8%           11.2%          7.6%

      TOPAMAX
      -------
      US         1,674  1,471     13.8%           13.8%            -
      Intl         377    330     14.2%            4.2%         10.0%
      WW         2,051  1,801     13.9%           12.1%          1.8%

      VELCADE
      -------
      US             4      5    -20.0%          -20.0%            -
      Intl         575    364     58.0%           44.8%         13.2%
      WW           579    369     56.9%           43.9%         13.0%

      OTHER
      -----
      US         1,858  1,788      3.9%            3.9%            -
      Intl       2,567  2,203     16.5%            4.1%         12.4%
      WW         4,425  3,991     10.9%            4.1%          6.8%

      TOTAL PHARMACEUTICAL
      --------------------
      US        11,401 11,659     -2.2%           -2.2%            -
      Intl       7,481  6,810      9.9%            0.0%          9.9%
      WW        18,882 18,469      2.2%           -1.5%          3.7%



      (1) Operational growth excludes the effect of currency
      (2) Select areas (unaudited)
      (3) Prior year amounts have been reclassified to conform with
          current presentation
      (4) For external purposes, reported as U.S. sales


                                          THIRD QUARTER

                                                    % Change

                  2008   2007 Reported      Operational (1)    Currency
                  ----   ---- --------      ---------------    --------


    MEDICAL DEVICES AND DIAGNOSTICS (2) (3)

    CORDIS (4)
    ----------
      US           277    373    -25.7%          -25.7%           -
      Intl         449    404     11.1%            4.2%         6.9%
      WW           726    777     -6.6%          -10.2%         3.6%

    DEPUY
    -----
      US           680    636      6.9%            6.9%           -
      Intl         515    450     14.4%            9.6%         4.8%
      WW         1,195  1,086     10.0%            8.0%         2.0%

    DIABETES CARE
    -------------
      US           349    321      8.7%            8.7%           -
      Intl         318    264     20.5%           12.3%         8.2%
      WW           667    585     14.0%           10.3%         3.7%

    ETHICON (5)
    -----------
      US           372    350      6.3%            6.3%           -
      Intl         585    531     10.2%            4.5%         5.7%
      WW           957    881      8.6%            5.2%         3.4%

    ETHICON ENDO-SURGERY
           --------------------
      US           473    440      7.5%            7.5%           -
      Intl         569    482     18.0%           11.4%         6.6%
      WW         1,042    922     13.0%            9.5%         3.5%

    ORTHO-CLINICAL DIAGNOSTICS (5)
    ------------------------------
      US           261    235     11.1%           11.1%           -
      Intl         209    185     13.0%            6.4%         6.6%
      WW           470    420     11.9%            9.0%         2.9%

    VISION CARE
    -----------
      US           236    214     10.3%           10.3%           -
      Intl         416    363     14.6%            8.3%         6.3%
      WW           652    577     13.0%            9.0%         4.0%

    TOTAL MEDICAL DEVICES AND DIAGNOSTICS
    -------------------------------------
      US         2,648  2,569      3.1%            3.1%           -
      Intl       3,061  2,679     14.3%            8.0%         6.3%
      WW         5,709  5,248      8.8%            5.6%         3.2%


                                        NINE MONTHS

                                                % Change


                  2008   2007 Reported     Operational (1)     Currency
                  ----   ---- --------     ---------------     --------

    CORDIS (4)
    ----------
      US           982  1,194    -17.8%          -17.8%           -
      Intl       1,431  1,363      5.0%           -4.6%         9.6%
      WW         2,413  2,557     -5.6%          -10.7%         5.1%

    DEPUY
    -----
      US         2,076  1,977      5.0%            5.0%           -
      Intl       1,661  1,401     18.6%            9.1%         9.5%
      WW         3,737  3,378     10.6%            6.7%         3.9%

    DIABETES CARE
    -------------
      US           990    923      7.3%            7.3%           -
      Intl         966    807     19.7%            8.0%        11.7%
      WW         1,956  1,730     13.1%            7.6%         5.5%

    ETHICON (5)
    -----------
      US         1,087  1,046      3.9%            3.9%           -
      Intl       1,835  1,613     13.8%            4.2%         9.6%
      WW         2,922  2,659      9.9%            4.1%         5.8%

    ETHICON ENDO-SURGERY
    --------------------
      US         1,386  1,311      5.7%            5.7%           -
      Intl       1,783  1,459     22.2%           11.3%        10.9%
      WW         3,169  2,770     14.4%            8.7%         5.7%

    ORTHO-CLINICAL DIAGNOSTICS (5)
    ------------------------------
      US           749    699      7.2%            7.2%           -
      Intl         640    550     16.4%            6.0%        10.4%
      WW         1,389  1,249     11.2%            6.6%         4.6%

    VISION CARE
    -----------
      US           689    622     10.8%           10.8%           -
      Intl       1,209  1,021     18.4%            9.0%         9.4%
      WW         1,898  1,643     15.5%            9.6%         5.9%

    TOTAL MEDICAL DEVICES AND DIAGNOSTICS
    -------------------------------------
      US         7,959  7,772      2.4%            2.4%           -
      Intl       9,525  8,214     16.0%            6.0%        10.0%
      WW        17,484 15,986      9.4%            4.3%         5.1%



      (1) Operational growth excludes the effect of currency
      (2) Select areas (unaudited)
      (3) Prior year amounts have been reclassified to conform with
          current presentation
      (4) Includes sales of Drug-Eluting Stents for Q3 2008 of $97,
          $192 and $289 million Domestic, International and Worldwide
          respectively

          Includes sales of Drug-Eluting Stents for Q3 2007 of $184,
          $193 and $377 million Domestic, International and Worldwide
          respectively

          Includes sales of Drug-Eluting Stents for Sept YTD 2008 of
          $433, $650 and $1,083 million Domestic, International and
          Worldwide respectively

          Includes sales of Drug-Eluting Stents for Sept YTD 2007 of $629,
          $718 and $1,347 million Domestic, International and Worldwide
          respectively
      (5) Restated to include portion of sales previously reported in
          the "Other" category



                                          THIRD QUARTER

                                                % Change

                  2008   2007 Reported      Operational (1)    Currency
                  ----   ---- --------      ---------------    --------


      CONSUMER SEGMENT (2)
      ---------------------

    SKIN CARE
    ---------
    US             358    311    15.1%              15.1%           -
    Intl           500    426    17.4%               9.7%         7.7%
    WW             858    737    16.4%              12.0%         4.4%

    BABY CARE
    ---------
    US             114    113     0.9%               0.9%           -
    Intl           472    398    18.6%              11.7%         6.9%
    WW             586    511    14.7%               9.4%         5.3%

    ORAL CARE
    ---------
    US             204    211    -3.3%              -3.3%           -
    Intl           230    185    24.3%              18.1%         6.2%
    WW             434    396     9.6%               6.7%         2.9%

    OTC/NUTRITIONALS
    ----------------
    US             778    653    19.1%              19.1%           -
    Nutritionals
    Intl           661    611     8.2%               2.9%         5.3%
    WW           1,439  1,264    13.8%              11.3%         2.5%

    WOMEN'S HEALTH
    --------------
    US             164    149    10.1%              10.1%           -
    Intl           346    312    10.9%               3.3%         7.6%
    WW             510    461    10.6%               5.5%         5.1%

    WOUND CARE / OTHER
    ------------------
    US             151    154    -1.9%              -1.9%           -
    Intl           121    100    21.0%              13.6%         7.4%
    WW             272    254     7.1%               4.2%         2.9%

    TOTAL CONSUMER
    --------------
    US           1,769  1,591    11.2%              11.2%           -
    Intl         2,330  2,032    14.7%               8.1%         6.6%
    WW           4,099  3,623    13.1%               9.4%         3.7%


                                        NINE MONTHS

                                                % Change


                  2008   2007   Reported     Operational (1)     Currency
                  ----   ----   --------     ---------------     --------

    SKIN CARE
    ---------
    US           1,119  1,006    11.2%              11.2%           -
    Intl         1,418  1,252    13.3%               3.5%         9.8%
    WW           2,537  2,258    12.4%               6.9%         5.5%

    BABY CARE
    ---------
    US             340    328     3.7%               3.7%           -
    Intl         1,351  1,117    20.9%              11.6%         9.3%
    WW           1,691  1,445    17.0%               9.8%         7.2%

    ORAL CARE
    ---------
    US             588    600    -2.0%              -2.0%           -
    Intl           640    509    25.7%              16.3%         9.4%
    WW           1,228  1,109    10.7%               6.4%         4.3%

    OTC/NUTRITIONALS
    ----------------
    US           2,299  1,892    21.5%              21.5%           -
    Intl         2,139  1,835    16.6%               6.6%        10.0%
    WW           4,438  3,727    19.1%              14.2%         4.9%

    WOMEN'S HEALTH
    --------------
    US             470    475    -1.1%              -1.1%           -
    Intl         1,005    870    15.5%               4.9%        10.6%
    WW           1,475  1,345     9.7%               2.9%         6.8%

    WOUND CARE / OTHER
    ------------------
    US             466    481     -3.1%             -3.1%           -
    Intl           364    318     14.5%              4.1%        10.4%
    WW             830    799      3.9%             -0.3%         4.2%

    TOTAL CONSUMER
    --------------
    US           5,282  4,782     10.5%             10.5%           -
    Intl         6,917  5,901     17.2%              7.3%         9.9%
    WW          12,199 10,683     14.2%              8.7%         5.5%


      (1) Operational growth excludes the effect of currency
      (2) Select areas (unaudited)


SOURCE Johnson & Johnson

 
http://www.jnj.com

 

Copyright © 2008 PR Newswire. All rights reserved

News Provided by COMTEX


Close window | Back to top

Copyright 2014 Johnson & Johnson

This site is governed solely by applicable U.S laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy.Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson.Contact Us with any questions or search this site for more information.